GANTANOL
LOE ApproachingNDAORALTABLET
Approved
Aug 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GANTANOL is an oral tablet small-molecule drug approved by Roche in 1965. The generic name and mechanism of action are not currently specified in available records. As a legacy product, it represents a historical asset in Roche's portfolio with limited modern clinical context.
LOE Approaching
With LOE approaching and minimal linked job activity, the commercial team is likely in maintenance mode with reduced headcount and limited expansion opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job postings indicate declining investment in GANTANOL. Roles on this product are primarily maintenance-focused, managing a brand in its final commercial phase with limited growth or innovation opportunity.
Brand ManagerField Sales Representative
Worked on GANTANOL at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.